News

Public · Published

Truist Securities maintains Amgen at Hold, raises price target to $398 from $380

Truist Securities kept its Hold rating on Amgen and raised its price target from $380 to $398, a 4.7% increase. The new target implies 13.7% downside from Amgen's Nov. 3 closing price of $461.26.

Published:

Updated:

What happened

Truist Securities kept its Hold rating on Amgen and raised its price target from $380 to $398, a 4.7% increase. The new target implies 13.7% downside from Amgen’s Nov. 3 closing price of $461.26.

Confirmed

Global impact / market context

Truist’s higher target suggests a modestly improved valuation view, but the unchanged Hold rating means its recommendation did not change. Because the target remains below the cited closing price, investor expectations could be affected if other analysts or investors adjust their views of Amgen’s shares.

Analyst inference

Recent analyst targets cited in the article span $378 to $480, with Truist’s new $398 target within that range. These differing estimates could influence investor positioning and, if they lead investors to trade Amgen shares, affect demand for the stock; they do not establish which view is accurate.

Analyst inference

What to watch

  1. Check whether Truist changes its Hold rating or target in later updates; a further increase or cut would show whether this revised valuation view is sustained. Analyst inference
  2. Compare future analyst targets with the article’s $378-to-$480 range to see whether estimates converge, potentially narrowing disagreement about Amgen’s value, or remain widely spread. Analyst inference
  3. Compare Amgen’s share price with Truist’s $398 target and the Nov. 3 close of $461.26; the article gives no later price data to assess the gap. Confirmed

Evidence

  • Original source link unavailable